Company intelligence / Profile preview

Dedicaid

Vienna, Austria

Ownership: Private
Development stage: Other

Overview

Dedicaid developed an AI-powered clinical decision support software platform capable of generating indication-specific applications from imaging datasets. The platform was validated for prostate, breast, and lung cancer applications with proof of concept published in peer-reviewed journals. It differed from commercially available solutions by offering predictive capabilities beyond image interpretation, including disease severity prediction, patient risk assessment, and treatment decision support.

Therapeutic areas: Oncology
Modalities: Software as a Medical Device
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Dedicaid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dedicaid.

Explore the full profile